| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 06/07/2006 | EP1492789B1 Tropane derivatives as ccr5 modulators |
| 06/07/2006 | EP1441591A4 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
| 06/07/2006 | EP1421075B1 Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv |
| 06/07/2006 | EP1409673B1 Human leucine-rich repeat containing protein, expressed predominantely in small intestine, hlrrsi1 |
| 06/07/2006 | EP1406878B1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 06/07/2006 | EP1378510B1 Triazaspiro (5.5) undecane derivatives and drugs containing the same as the active ingredient |
| 06/07/2006 | EP1368355B1 Substituted pyrazolopyrimidines and thiazolopyrimidines |
| 06/07/2006 | EP1364023B1 Gene highly expressed in cartilage tissues |
| 06/07/2006 | EP1320552B8 Method for producing human anti-thymocyte immunoglobulins |
| 06/07/2006 | EP1309559B1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 06/07/2006 | EP1265630B1 Use of insulin for the treatment of cartilagenous disorders |
| 06/07/2006 | EP1254234B1 Haemophilus influenza outer membrane protein and use thereof in vaccination |
| 06/07/2006 | EP1165112B1 Modulators of polysaccharides and uses thereof |
| 06/07/2006 | EP1105419B1 Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| 06/07/2006 | EP1095059B1 Chemotaxis inhibiting protein of staphylococcus (chips) and its use |
| 06/07/2006 | EP1071463B1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 06/07/2006 | EP1002081B1 Delayed progression to aids by a missense allele of the ccr2 gene |
| 06/07/2006 | EP0969873B1 Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
| 06/07/2006 | EP0813538B1 Compositions and methods for the treatment and diagnosis of immune disorders |
| 06/07/2006 | EP0772437B1 Compositions for delivery of genetic material |
| 06/07/2006 | CN1784410A Protein kinase inhibitors |
| 06/07/2006 | CN1784403A Azaindole compounds as kinase inhibitors |
| 06/07/2006 | CN1784402A Imidazo and thiazolopyridines as JAK3 kinase inhibitors |
| 06/07/2006 | CN1784231A 1-amino 1H-imidazoquinolines |
| 06/07/2006 | CN1784224A Composition for preventing or treating allergic disease using black rice extract and its therapeutic use |
| 06/07/2006 | CN1782058A Full scorpion obstruction removing wine and its preparing process |
| 06/07/2006 | CN1781947A Modified peptides as therapeutic agents |
| 06/07/2006 | CN1781946A Modified peptides as therapeutic agents |
| 06/07/2006 | CN1781945A Modified peptides as therapeutic agents |
| 06/07/2006 | CN1781941A Protein Akaan 1 extracted from antrodia camphorata and its use in regulating immune function |
| 06/07/2006 | CN1781933A Thymosin alpha 1 active segment cyclicpeptide analogue and its poly glycol derivative |
| 06/07/2006 | CN1781920A Polycyclic guanine phosphodiesterase v inhibitor |
| 06/07/2006 | CN1781890A 糖皮质激素受体调制剂 Glucocorticoid receptor modulators |
| 06/07/2006 | CN1781529A Liuweidihuang multiple vatimines and its preparing method |
| 06/07/2006 | CN1781501A Glossy ganoderma essence powder and its preparing method |
| 06/07/2006 | CN1781384A Donkey-hide gelatine paste and its preparing method |
| 06/07/2006 | CN1258551C Preparing method of degradable polymer |
| 06/07/2006 | CN1258537C Method for preparing polypeptide soluble in aqueous solvent in absence of detergent |
| 06/07/2006 | CN1258533C Antihistaminic spiro compounds |
| 06/06/2006 | US7057076 which have improved receptor binding affinity via substituted alkyl side chains at the c-3 position; may contain terpene funtionality combined with resorcinol moieties; for treatment of nervous system disorders and cardiovascular disorders |
| 06/06/2006 | US7057022 Antibodies which specifically bind to TNF-R |
| 06/06/2006 | US7056944 Pyrazole compositions useful as inhibitors of erk |
| 06/06/2006 | US7056938 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 06/06/2006 | US7056934 use in treating respiratory system disorders such as asthma, incipient asthma and wheezy infant syndrome, chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic eosinophilic pneumonia, chronic obstructive pulmonary disease, allergies |
| 06/06/2006 | US7056933 For therapy of arthritis, fever, common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, etc. |
| 06/06/2006 | US7056915 Compounds useful as reversible inhibitors of cysteine proteases |
| 06/06/2006 | US7056914 Benzoxazinone-derived compounds, their preparation and use as medicaments |
| 06/06/2006 | US7056904 Therapy for bone disorders; osteoporosis; vitamin deficiency |
| 06/06/2006 | US7056903 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists |
| 06/06/2006 | US7056898 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 06/06/2006 | US7056895 1-(3,4-dihydroxy-5-methylol-tetrahydrofur-2-yl),3-amidino-1H-1,2,4- triazoles; infections, infestations, autoimmune diseases; anticarcinogenic and -tumor agents; HIV, hepatitis C, human papilloma virus and giant cell arteritis |
| 06/06/2006 | US7056884 Reduced FK228 and use thereof |
| 06/06/2006 | US7056704 RNA interference mediating small RNA molecules |
| 06/06/2006 | US7056677 Soluble mast cell function associated antigen (MAFA) pharmaceutical compositions and methods of making and using them |
| 06/06/2006 | US7056502 Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
| 06/06/2006 | CA2327723C Bicyclic hydroxamic acid derivatives |
| 06/06/2006 | CA2154572C Use of riluzole for the treatment of neuro-sida |
| 06/01/2006 | WO2006058316A1 Dosage regimen of an s1p receptor agonist |
| 06/01/2006 | WO2006058120A1 Bicyclic inhibitors or rho kinase |
| 06/01/2006 | WO2006058077A1 Dap-10 and uses thereof |
| 06/01/2006 | WO2006057932A2 2-METHYLENE-18,19-DINOR-1α-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES |
| 06/01/2006 | WO2006057902A2 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 06/01/2006 | WO2006057901A2 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES |
| 06/01/2006 | WO2006057900A2 17,20(z)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | WO2006057899A2 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| 06/01/2006 | WO2006057886A2 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES |
| 06/01/2006 | WO2006057885A2 17,20(e)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | WO2006057884A2 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES |
| 06/01/2006 | WO2006057870A1 Potentiators of glutamate receptors |
| 06/01/2006 | WO2006057869A1 Potentiators of glutamate receptors |
| 06/01/2006 | WO2006057860A1 Potentiators of glutamate receptors |
| 06/01/2006 | WO2006057270A1 Nitrogeneous tricyclic compound |
| 06/01/2006 | WO2006056848A1 Octahydropyrrolo[3,4-c]pyrrole derivatives |
| 06/01/2006 | WO2006056783A2 Structured phospholipids for treating autoimmune and neurodegenerative diseases |
| 06/01/2006 | WO2006056492A1 Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis |
| 06/01/2006 | WO2006056479A1 Sly1 inhibitors in transplantation |
| 06/01/2006 | WO2006056245A1 Use of a human chitinase-like protein in diagnosis and therapy |
| 06/01/2006 | WO2006056142A1 Cpg single-strand deoxynucleotides for use as adjuvant |
| 06/01/2006 | WO2006056027A1 Human cytomegalovirus immunotherapy |
| 06/01/2006 | WO2006018185A8 Dihydropteridinones for the treatment of cancer diseases |
| 06/01/2006 | WO2006014706A3 Methotrexate derivatives useful for treating cancer and arthritis |
| 06/01/2006 | WO2005107752A3 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 06/01/2006 | WO2003025542A3 Immune response associated proteins |
| 06/01/2006 | US20060116518 Novel phenanthridines |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116388 CXCR3 antagonists |
| 06/01/2006 | US20060116363 Tricyclic derivatives as ltd4 antagonists |
| 06/01/2006 | US20060115813 Intracellular signaling molecules |
| 06/01/2006 | US20060115542 Therapeutic delivery of carbon monoxide |
| 06/01/2006 | US20060115533 Pharmaceutical compositions |
| 06/01/2006 | US20060115500 Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| 06/01/2006 | US20060115470 Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| 06/01/2006 | CA2590349A1 Potentiators of glutamate receptors |
| 06/01/2006 | CA2589265A1 Dosage regimen of an s1p receptor agonist |
| 06/01/2006 | CA2588881A1 Potentiators of glutamate receptors |
| 06/01/2006 | CA2588412A1 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 06/01/2006 | CA2588406A1 2-.alpha.-methyl and 2-.beta.-methyl analogs of 19,26,27-trinor-(20s-1.alpha.-hydroxyvitamin d3 and their uses |
| 06/01/2006 | CA2588401A1 17,20(z)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | CA2588399A1 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| 06/01/2006 | CA2588396A1 17,20(e)-dehydro vitamin d analogs and their uses |